



**海普瑞**

**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**

**(深圳市海普瑞藥業集團股份有限公司)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

*(於中華人民共和國註冊成立的股份有限公司)*

**GLOBAL OFFERING**

**Number of Offer Shares under the Global Offering** : 220,094,500 H Shares (subject to the Over-allotment Option)  
**Number of Hong Kong Offer Shares** : 22,010,000 H Shares (subject to adjustment)  
**Number of International Offer Shares** : 198,084,500 H Shares (subject to adjustment and the Over-allotment Option)  
**Minimum Offer Price** : HK\$20.60 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund)  
**Nominal Value** : RMB1.00 per H Share  
**Stock code** : 9989

**全球發售**

**全球發售項下的發售股份數目** : 220,094,500股H股(視乎超額配售權行使與否而定)  
**香港發售股份數目** : 22,010,000股H股(可予調整)  
**國際發售股份數目** : 198,084,500股H股(可予調整及視乎超額配售權行使與否而定)  
**最高發售價** : 每股H股20.60港元, 另加1.0%經紀佣金、0.0027%證監會交易徵費及0.005%香港聯交所交易費(須於申請時以港元繳足, 多繳股款可予退還)  
**面值** : 每股H股人民幣1.00元  
**股份代號** : 9989

Please read carefully the prospectus of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company") dated Wednesday, June 24 2020 (the "Prospectus") (in particular, the section on "How to Apply for the Hong Kong Offer Shares" in the Prospectus) and the guidelines on the back of this Application Form before completing this Application Form. Terms used in this Application Form shall have the same meanings as those defined in the Prospectus unless defined herein.

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "SEHK") and Hong Kong Securities Clearing Company Limited ("CC") take no responsibility for the contents of this Application Form, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of this Application Form.

A copy of this Application Form, together with a copy of each of the White Form and E-Form Application Forms, the Prospectus and the other documents specified in the section headed "Documents Delivered to the Registrar of Companies in Hong Kong and Available for Inspection — Documents Delivered to the Registrar of Companies in Hong Kong" in Appendix VII to the Prospectus have been registered by the Registrar of Companies in Hong Kong as required by Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). The Securities and Futures Commission (the "SFC") and the Registrar of Companies in Hong Kong take no responsibility as to the contents of any of these documents.

Your attention is drawn to the paragraph headed "Personal Information Collection Statement" which sets out the policies and practices of the Company and its H Share Registrar in relation to personal data and compliance with the Personal Data (Privacy) Ordinance.

Nothing in this Application Form or the Prospectus constitutes an offer to sell or the solicitation of an offer to buy nor shall there be any sale of Hong Kong Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. This Application Form and the Prospectus are not for distribution, directly or indirectly, in or into the United States, nor is this application an offer of Shares for sale in the United States. The Offer Shares have not been and will not be registered under the U.S. Securities Act or any state securities law in the United States and may not be offered, sold, pledged or transferred within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and the applicable laws of each jurisdiction where those offers and sales occur. No public offering of the Offer Shares will be made in the United States.

This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction. This Application Form and the Prospectus are addressed to you personally. Any forwarding or distribution or reproduction of this Application Form or the Prospectus in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the U.S. Securities Act or the applicable laws of other jurisdictions.

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to adjustment as described in the section headed "Structure of the Global Offering — The Hong Kong Public Offering — Reallocation" in the Prospectus. In particular, the Joint Global Coordinators may reallocate Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, if such reallocation is done other than pursuant to Practice Note 18 of the Listing Rules, the number of Offer Shares that may be reallocated from the International Offering to the Hong Kong Public Offering shall not exceed 22,010,000 H Shares, representing approximately 10% of the Offer Shares initially available under the Global Offering, increasing the total number of Offer Shares available under the Hong Kong Public Offering to 44,020,000 H Shares, representing approximately 20% of the Offer Shares initially available under the Global Offering and the final Offer Price shall be fixed at the bottom end of the indicative Offer Price range (i.e. HK\$18.40 per Offer Share) stated in the Prospectus.

If the number of Offer Shares validly applied for in the Hong Kong Public Offering represents (i) 15 times or more but less than 50 times, (ii) 50 times or more but less than 100 times, and (iii) 100 times or more, of the number of Hong Kong Offer Shares available under the Hong Kong Public Offering, then Offer Shares will be reallocated to the Hong Kong Public Offering from the International Offering. The total number of Offer Shares available under the Hong Kong Public Offering will be increased to 66,029,000 Offer Shares (in the case of (i)), 88,038,000 Offer Shares (in the case of (ii)), and 110,048,000 Offer Shares (in the case of (iii)), respectively, representing approximately 30%, 40%, and 50% of the total number of Offer Shares initially available under the Global Offering, respectively (before any exercise of the Over-allotment Option). Further details of the reallocation are stated in the paragraph headed "Structure of the Global Offering — Hong Kong Public Offering — Reallocation" of the Prospectus.

To: Shenzhen Hepalink Pharmaceutical Group Co., Ltd.  
 Joint Sponsors  
 Joint Global Coordinators  
 Joint Bookrunners  
 The Hong Kong Underwriters

**I** We confirm that we have (i) complied with the Guidelines for Electronic Public Offerings and the Operational Procedures for HK eIPO White Form Applications submitted via banks/stockbrokers and all applicable laws and regulations (whether statutory or otherwise) in relation to the provision of our HK eIPO White Form service in connection with the Hong Kong Public Offering; and (ii) read the terms and conditions and application procedures set out in the Prospectus and this Application Form and agree to be bound by them. Applying on behalf of each of the underlying applicants to whom this application relates, we:

- **apply** for the number of Hong Kong Offer Shares set out below, on the terms and conditions of the Prospectus and this Application Form, and subject to the Articles of Association;
- **enclose** payment in full for the Hong Kong Offer Shares applied for, including brokerage of 1%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%;
- **confirm** that the underlying applicants have undertaken and agreed to accept the Hong Kong Offer Shares applied for, or any lesser number allocated to such underlying applicants on this application;
- **undertake and confirm** that the underlying applicant(s) and the person for whose benefit the underlying applicant(s) is/are applying has/have not applied for or taken up, or indicated an interest for, or received or been placed or allocated (including conditionally and/or provisionally), and will not apply for or take up, or indicate an interest for, any International Offering nor otherwise participate in the International Offering;
- **understand** that these declarations and representations will be relied upon by the Company and the Joint Global Coordinators in deciding whether or not to make any allotment of Hong Kong Offer Shares in response to this application, and that the underlying applicants may be prosecuted if they made a false declaration;
- **authorize** the Company to place the name(s) of the underlying applicant(s) on the H Share register of members of the Company as the holder(s) of any Hong Kong Offer Shares to be allotted to them, and (subject to the terms and conditions set out in this Application Form) to send any H Share certificate(s) and/or any refund cheque(s) (where applicable) by ordinary post at that underlying applicant's own risk to the address stated on this Application Form in accordance with the procedures prescribed in this Application Form and in the Prospectus;
- **request** that any e-Auto Refund payment instructions be dispatched to the application payment account where the applicants had paid the application monies from a single bank account;
- **request** that any refund cheque(s) be made payable to the underlying applicant(s) who had used multiple bank accounts to pay the application monies and to send any such refund cheque(s) by ordinary post at that underlying applicant's own risk to the address stated on the application in accordance with the procedures prescribed in this Application Form and in the Prospectus;
- **confirm** that each underlying applicant has read the terms and conditions and application procedures set out in this Application Form and in the Prospectus and in the IPO App and in the designated website at www.hkeipo.hk under the HK eIPO White Form service and agrees to be bound by them;
- **represent warrant and undertake:** (a) that the underlying applicant(s) and any persons for whose benefit the underlying applicant(s) is/are applying is not restricted by any applicable laws of Hong Kong or elsewhere from making this application, paying any application monies for, or being allocated or taking up, any Hong Kong Offer Shares and the underlying applicant(s) and any persons for whose benefit the underlying applicant(s) is/are applying is/are outside the United States when completing and submitting the application and is/are a person described in paragraph (b)(3) of Rule 902 of Regulation S and the underlying applicant(s) and any persons for whose benefit and the underlying applicant(s) is/

## DE E C E I I A ICA I F F

References to boxes below are to the numbered boxes on this Application Form.

### 1 Sign and date the Application Form in Box 1. Only written signatures will be accepted.

The name and the representative capacity of the signatory should also be stated.

To apply for Hong Kong Offer Shares using this Application Form, you must be named in the list of **HK eIPO White Form** Service Provider who may provide **HK eIPO White Form** service in relation to the Hong Kong Public Offering, which was released by the SFC.

### 2 Put in Box 2 (in figures) the total number of Hong Kong Offer Shares for which you wish to apply on behalf of the underlying applicants.

Application details of the underlying applicants on whose behalf you are applying must be contained in one data file in read-only CD-ROM format submitted together with this Application Form.

### 3 Complete your payment details in Box 3.

You must state in this box the number of cheques you are enclosing together with this Application Form; and you must state on the reverse of each of those cheques (i) your **HK eIPO White Form** Service Provider ID; and (ii) the file number of the data file containing application details of the underlying applicant(s).

The dollar amount(s) stated in this box must be equal to the amount payable for the total number of Hong Kong Offer Shares applied for in Box 2. All cheque(s) and this Application Form together with a sealed envelope containing the CD-ROM, if any, must be placed in the envelope bearing your company chop.

For payments by cheque, the cheque must:

- be in Hong Kong dollars;
- not be post dated;
- be drawn on a Hong Kong dollar bank account in Hong Kong;
- show your (or your nominee's) account name;
- be made payable to "BANK OF CHINA (HONG KONG) NOMINEES LIMITED SHENZHEN HEPALINK PHARMACEUTICAL PUBLIC OFFER";
- be crossed "Account Payee Only"; and
- be signed by the authorized signatories of the **HK eIPO White Form** Service Provider.

Your application may be rejected if any of these requirements is not met or if the cheque is dishonored on its first presentation.

It is your responsibility to ensure that details on the cheque(s) submitted correspond with the application details contained in the CD-ROM or data file submitted in respect of this application. The Company and the Joint Global Coordinators have full discretion to reject any applications in the case of discrepancies.

No receipt will be issued for sums paid on application.

### 4 Insert your details in Box 4 (using BLOCK letters).

You should write the name, ID and address of the **HK eIPO White Form** Service Provider in this box. You should also include the name and telephone number of the contact person at your place of business and where applicable, the Broker No. and Broker's Chop.

#### Personal Information Collection Statement

The main provisions of the Personal Data (Privacy) Ordinance (the "Ordinance") came into effect in Hong Kong on December 20, 1996. This Personal Information Collection Statement informs the applicant for and holder of the H Shares of the policies and practices of the Company and the H Share Registrar in relation to personal data and the Ordinance.

#### 1. Reasons for the collection of your personal data

From time to time it is necessary for applicants for securities or registered holders of securities to supply their latest correct personal data to the Company and/or the H Share Registrar when applying for securities or transferring securities into or out of their names or in procuring the services of the H Share Registrar.

Failure to supply the requested data may result in your application for securities being rejected or in delay or inability of the Company and/or the H Share Registrar to effect transfers or otherwise render their services. It may also prevent or delay registration or transfer of the Hong Kong Offer Shares which you have successfully applied for and/or the despatch of H Share certificate(s), and/or the despatch of e-Auto Refund payment instructions, and/or the despatch of refund cheque(s) to which you are entitled.

It is important that the applicants and the holders of securities inform the Company and the H Share Registrar immediately of any inaccuracies in the personal data supplied.

#### 2. Purposes

The personal data of the applicants and holders of securities may be used, held and/or stored (by whatever means) for the following purposes:

- processing of your application and e-Auto Refund payment instructions/refund cheque, where applicable, and verification of compliance with the terms and application procedures set out in this Application Form and the Prospectus and announcing results of allocations of the Hong Kong Offer Shares;
- enabling compliance with all applicable laws and regulations in Hong Kong and elsewhere;
- registering new issues or transfers into or out of the names of holders of securities including, where applicable, in the name of HKSCC Nominees;
- maintaining or updating the registers of holders of securities of the Company;
- conducting or assisting to conduct signature verifications, any other verification or exchange of information;
- establishing benefit entitlements of holders of securities of the Company, such as dividends, rights issues and bonus issues, etc;
- distributing communications from the Company and its subsidiaries;
- compiling statistical information and Shareholder profiles;
- making disclosures as required by laws, rules or regulations;
- disclosing identities of successful applicants by way of press announcement(s) or otherwise;
- disclosing relevant information to facilitate claims on entitlements; and
- any other incidental or associated purposes relating to the above and/or to enable the Company and the H Share Registrar to discharge their obligations to holders of securities and/or regulators and any other purpose to which the holders of securities may from time to time agree.

#### 3. Transfer of personal data

Personal data held by the Company and the H Share Registrar relating to the applicants and the holders of securities will be kept confidential but the Company and its H Share Registrar may, to the extent necessary for achieving the above purposes or any of them, make such enquiries as they consider necessary to confirm the accuracy of the personal data and in particular, they may disclose, obtain, transfer (whether within or outside Hong Kong) the personal data of the applicants and the holders of securities to, from or with any and all of the following persons and entities:

- the Company or its appointed agents such as financial advisers, receiving banks and overseas principal registrars;
- where applicants for securities request deposit into CCASS, HKSCC and HKSCC Nominees, who will use the personal data for the purposes of operating CCASS;
- any agents, contractors or third-party service providers who offer administrative, telecommunications, computer, payment or other services to the Company and/or the H Share Registrar in connection with the operation of their respective businesses;
- the Hong Kong Stock Exchange, the SFC and any other statutory regulatory or governmental bodies or otherwise as required by laws, rules or regulations; and
- any other persons or institutions with which the holders of securities have or propose to have dealings, such as their bankers, solicitors, accountants or stockbrokers, etc.

#### 4. Access and correction of personal data

The Ordinance provides the applicants and the holders of securities with rights to ascertain whether the Company and/or the H Share Registrar hold their personal data, to obtain a copy of that data, and to correct any data that is inaccurate. In accordance with the Ordinance, the Company and the H Share Registrar have the right to charge a reasonable fee for the processing of any data access request. All requests for access to data or correction of data should be addressed to us, at our registered address disclosed in the "Corporate Information" section of the Prospectus or as notified from time to time, for the attention of the company secretary, or our H Share Registrar for the attention of the privacy compliance officer.

By signing an Application Form, you agree to all of the above.

#### DELIVERY OF THIS APPLICATION FORM

This completed Application Form, together with the appropriate cheque(s) together with a sealed envelope containing the CD-ROM, must be submitted to the following receiving banks by 4:00 p.m. on Tuesday, June 30 2020:

Bank of China (Hong Kong) Limited  
6/F, Bank of China Centre,  
11 Hoi Fai Road,  
West Kowloon

## 填寫本申請表格的指引

下文各欄提述的號碼乃本申請表格中各欄的編號。

### 1 在申請表格欄1簽署及填上日期。只接受親筆簽名。

亦必須註明簽署人的姓名、名稱及代表身份。

如欲使用本申請表格申請認購香港發售股份，閣下必須為名列於證監會公佈的網上白表服務供應商名單內可就香港公開發售提供網上白表服務的供應商。

### 2 在欄2填上閣下欲代表相關申請人申請認購的香港發售股份總數(以數字填寫)。

閣下代相關申請人作出申請的申請資料必須包含於連同本申請表格一併遞交的唯讀光碟格式的一個資料檔案內。

### 3 在欄3填上閣下付款的詳細資料。

閣下必須在本欄註明閣下連同本申請表格隨附的支票數目；及閣下必須在每張支票的背面註明(i)閣下的網上白表服務供應商編號；及(ii)載有相關申請人詳細申請資料的資料檔案編號。

本欄所註明的金額必須與欄2所申請認購的香港發售股份總數應付金額相同。所有支票及本申請表格連同裝有唯讀光碟的密封信封(如有)必須放進蓋上閣下公司印章的信封內。

如以支票繳付股款，則該支票必須：

- 為港元支票；
- 不得為期票；
- 由在香港的港元銀行賬戶開出；
- 顯示閣下(或閣下代名人)的賬戶名稱；
- 註明抬頭人為「中國銀行(香港)代理人有限公司—深圳市海普瑞藥業公開發售」；
- 劃線註明「只准入抬頭人賬戶」；及
- 由網上白表服務供應商的授權簽署人簽署。

倘未能符合任何此等規定或倘支票首次過戶不獲兌現，閣下的申請可能會遭拒絕受理。

閣下有責任確保所遞交支票上的詳細資料與就本申請遞交的唯讀光碟或資料檔案所載的申請詳情相同。倘出現差異，本公司及聯席全球協調人有絕對酌情權拒絕接受任何申請。

申請時繳付的款項將不會獲發收據。

### 4 在欄4填上閣下的詳細資料(用正楷填寫)。

閣下必須在本欄填上網上白表服務供應商的名称、編號及地址。閣下亦必須填寫閣下營業地點的聯絡人士姓名及電話號碼及(如適用)經紀號碼及蓋上經紀印章。

#### 個人資料收集聲明

《個人資料(私隱)條例》(「《條例》」)中的主要條文於1996年12月20日在香港生效。此份個人資料收集聲明是向H股申請人及持有人說明本公司及H股證券登記處有關個人資料及《條例》的政策及慣例。

#### 1. 收集閣下個人資料的原因

證券申請人或證券登記持有人以本身名義申請證券或轉讓或受讓證券時，或尋求H股證券登記處的服務時，須不時向本公司及或H股證券登記處提供其最新的正確個人資料。

若未能提供所需資料，可能會導致閣下的證券申請遭拒絕受理或本公司及或H股證券登記處延遲或無法進行過戶或提供服務，亦可能妨礙或延誤閣下成功申請的香港發售股份登記或過戶及或妨礙或延誤寄發H股股票，及或發送電子自動退款指示，及或寄發閣下應得的退款支票。

證券申請人及持有人提供的個人資料如有任何不確，必須即時知會本公司及H股證券登記處。

#### 2. 目的

證券申請人及持有人的個人資料可以任何方式被採用、持有及或保存，以作下列用途：

- 處理閣下的申請及電子自動退款指示、退款支票(如適用)、核實是否遵守本申請表格及招股章程所載條款及申請手續以及公佈香港發售股份的分配結果；
- 以遵守香港及其他地區的一切適用法律及法規；
- 以證券持有人(包括香港結算代理人(如適用))的名義登記新發行證券或轉讓或受讓證券；
- 存置或更新本公司證券持有人的名冊；
- 核對或協助進行簽名核對或任何其他資料的核對或交換；
- 確定本公司證券持有人可獲取的受益權利，例如股息、供股及紅股等；
- 分發本公司及其附屬公司的通訊；
- 編製統計數據及股東資料；
- 遵照法例、規則或規例的要求作出披露；
- 透過報章公佈或其他方式披露成功申請人士的身份；
- 披露有關資料以便作出權益索償；及
- 與上述有關的任何其他附帶或相關目的及或使本公司及H股證券登記處能履行對證券持有人及或監管機構承擔的責任及證券持有人不時同意的任何其他目的。

#### 3. 轉交個人資料

本公司及H股證券登記處會將其持有的證券申請人及持有人個人資料保密，但本公司及其H股證券登記處可能會就上述用途或上述任何用途作出彼等認為必要的查詢以確認個人資料的準確性，尤其可能會向下列任何及所有人士及實體披露、索取或轉交證券申請人及持有人的個人資料(不論在香港或外地)：

- 本公司或其委任的代理人，例如財務顧問、收款銀行及主要海外證券登記處；
- (倘證券申請人要求將證券存入中央結算系統)香港結算及香港結算代理人，彼等將會就中央結算系統的運作使用有關個人資料；
- 向本公司及或H股證券登記處提供與其各自業務營運有關的行政、電訊、電腦、付款或其他服務的任何代理人、承包商或第三方服務供應商；
- 香港聯交所、證監會及任何其他法定監管機關或政府部門或其他法例、規則或法規要求者；及
- 證券持有人與其進行或擬進行交易的任何其他人士或機構，例如彼等的銀行、律師、會計師或股票經紀等。

#### 4. 查閱和更正個人資料

《條例》賦予證券申請人及持有人權利以確定本公司及或H股證券登記處是否持有其個人資料、索取有關資料及更正任何不正確的資料。根據《條例》規定，本公司及H股證券登記處有權就處理任何查閱資料的要求收取合理費用。所有查閱資料或更正資料的要求應按招股章程「公司資料」一節所披露或不時通知的本公司註冊地址送交公司秘書，或向本公司的H股證券登記處的私隱條例事務主任提出。

閣下簽署申請表格，即表示同意上述各項。

#### 遞交本申請表格

經填妥的本申請表格，連同相關支票及裝有相關唯讀光碟的密封信封，必須於2020年6月30日(星期二)下午四時正之前，送達下列收款銀行：

中國銀行(香港)有限公司  
西九龍  
海輝道11號  
中銀中心6樓